Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 702,000 | 419,000 | 1,400,000 | 602,000 | 931,000 |
| Depreciation Amortization | 2,244,000 | 1,166,000 | 1,518,000 | 1,034,000 | 694,000 |
| Accounts receivable | -56,000 | 30,000 | -177,000 | -116,000 | -150,000 |
| Other Working Capital | -183,000 | -132,000 | -1,513,000 | -268,000 | -299,000 |
| Other Operating Activity | -782,000 | -909,000 | 1,975,000 | 781,000 | -360,000 |
| Operating Cash Flow | $1,925,000 | $574,000 | $3,203,000 | $2,033,000 | $816,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -28,000 | N/A | N/A | N/A | -800,000 |
| PPE Investments | -527,000 | -272,000 | -1,121,000 | -802,000 | -490,000 |
| Net Acquisitions | -5,632,000 | -7,555,000 | -55,000 | -48,000 | 18,000 |
| Purchase Of Investment | N/A | N/A | -2,823,000 | -982,000 | N/A |
| Sale Of Investment | N/A | -15,000 | 3,709,000 | N/A | N/A |
| Other Investing Activity | 27,000 | 1,688,000 | 42,000 | 34,000 | 28,000 |
| Investing Cash Flow | $-6,160,000 | $-6,154,000 | $-248,000 | $-1,798,000 | $-1,244,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | -1,767,000 | N/A | N/A |
| Debt Issued | N/A | N/A | 14,934,000 | N/A | N/A |
| Debt Repayment | -2,507,000 | -2,505,000 | -12,000 | -11,000 | -10,000 |
| Common Stock Issued | 186,000 | 129,000 | 248,000 | 206,000 | 130,000 |
| Common Stock Repurchased | -98,000 | -95,000 | -522,000 | -522,000 | -520,000 |
| Dividend Paid | -922,000 | -460,000 | -1,539,000 | -1,153,000 | -769,000 |
| Other Financing Activity | -1,442,000 | -1,468,000 | -195,000 | -877,000 | -442,000 |
| Financing Cash Flow | $-4,783,000 | $-4,399,000 | $11,147,000 | $-2,357,000 | $-1,611,000 |
| Exchange Rate Effect | 73,000 | 65,000 | -483,000 | -379,000 | -384,000 |
| Beginning Cash Position | 18,620,000 | 18,620,000 | 5,001,000 | 5,001,000 | 5,001,000 |
| End Cash Position | 9,675,000 | 8,706,000 | 18,620,000 | 2,500,000 | 2,578,000 |
| Net Cash Flow | $-8,945,000 | $-9,914,000 | $13,619,000 | $-2,501,000 | $-2,423,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,925,000 | 574,000 | 3,203,000 | 2,033,000 | 816,000 |
| Capital Expenditure | -527,000 | -272,000 | -1,121,000 | -802,000 | -490,000 |
| Free Cash Flow | 1,398,000 | 302,000 | 2,082,000 | 1,231,000 | 326,000 |